The introduction of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) further revolutionized diabetes management by stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying, thereby improving both postprandial glucose control and weight regulation (77). The gene discussed is GCG; the disease is diabetes mellitus.